Cardiff Oncology, Inc. - CRDF STOCK NEWS

Cardiff Oncology (Nasdaq: CRDF) has been added to the Russell 2000, Russell 3000, and Russell Microcap indexes effective June 28, 2021. This inclusion, part of the annual reconstitution, recognizes the company's market capitalization among the largest U.S. stocks as of May 7, 2021. Membership in these indexes provides increased visibility to institutional investors, as approximately $10.6 trillion in assets benchmark against Russell's indexes. Cardiff is focused on developing onvansertib for serious cancers, including KRAS-mutated colorectal and pancreatic cancers.

Cardiff Oncology (Nasdaq: CRDF) announced the appointment of Dr. Mani Mohindru and Dr. Renee P. Tannenbaum as independent board directors, replacing outgoing members Dr. Thomas Adams and Dr. Gary Jacob. This strategic move aims to enhance corporate governance and drive future growth. Dr. Mohindru brings extensive biotech leadership experience, while Dr. Tannenbaum adds expertise in business development and strategic partnerships. Both directors aim to advance the development of onvansertib, a drug targeting cancers with high medical need.

Cardiff Oncology (Nasdaq: CRDF) announced the first patient has been dosed in a Phase 2 trial of onvansertib, combined with nanoliposomal irinotecan and 5-FU, for metastatic pancreatic ductal adenocarcinoma (PDAC). This trial targets patients who failed prior gemcitabine therapy and aims to assess safety and preliminary efficacy across 40 patients at six U.S. sites. With PDAC's poor prognosis—7.7% response rate and 3.1-month median progression-free survival—onvansertib may improve treatment outcomes for those with KRAS mutations, prevalent in 95% of PDAC cases.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announces Dr. Mark Erlander will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company focuses on developing onvansertib, a first-in-class Polo-like Kinase 1 inhibitor for challenging cancers such as KRAS-mutated colorectal cancer and pancreatic cancer. Dr. Erlander's presentation is scheduled for June 1 at 4:00 PM ET. A replay will be available on the Cardiff Oncology website post-event. The company aims to improve cancer treatment responses and overall patient survival using advanced biomarker technology.

Cardiff Oncology (Nasdaq: CRDF) reported a strong start to 2021, highlighted by progress in clinical trials involving onvansertib for treating KRAS-mutated cancers, including colorectal and pancreatic cancers. The company raised $20 million through a common stock sale to support clinical development. Recent data show promising outcomes, with a median progression-free survival of 9.4 months in a metastatic colorectal cancer trial, significantly better than historical controls. Operating expenses rose to $5.5 million, reflecting advancements in drug development and clinical activities.

Cardiff Oncology, Inc. (CRDF) announced positive results from its ongoing Phase 1b/2 trial of onvansertib for KRAS-mutated metastatic colorectal cancer (mCRC). The trial reported a 39% overall response rate, with a median progression-free survival (mPFS) of 9.4 months, significantly surpassing historical mPFS rates. The treatment showed good tolerability with no major toxicities. Biomarker analyses indicate the potential of plasma KRAS mutant allelic frequency in predicting patient response. Upcoming results from the Phase 2 trial are anticipated later this year.

Cardiff Oncology (Nasdaq: CRDF) announced findings from its Expanded Access Program (EAP) for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) at the AACR Annual Meeting 2021. The program enrolled patients who failed multiple standard therapies, showing a median progression-free survival (mPFS) of 5.6 months, exceeding historical controls. 62.5% had a >50% decrease in KRAS MAF after one treatment cycle, indicating durable responses. Onvansertib was well-tolerated with no serious adverse events reported. The EAP has reached capacity and is no longer accepting new participants.

Cardiff Oncology (Nasdaq: CRDF) announced findings from its ongoing Phase 2 trial of onvansertib in mCRPC, presented at the AACR Annual Meeting 2021. The study reveals that the androgen receptor signaling inhibitor abiraterone enhances the efficacy of onvansertib by upregulating mitosis-related genes. These results support the hypothesis that combining these drugs could improve clinical outcomes for resistant patients. The poster presentation highlighted a specific gene signature that may predict patient responses, indicating a potential for precision medicine in ongoing trials.

Cardiff Oncology (CRDF), a clinical-stage biotech firm, is set to host a webinar on April 12, 2021, at 11 a.m. ET, focusing on onvansertib for treating KRAS-mutated metastatic colorectal cancer. Featured speakers include KOLs Dr. Daniel H. Ahn and Dr. Manish R. Sharma, who will address current treatment options and unmet needs. The CEO, Dr. Mark Erlander, will provide a corporate update. Cardiff is currently conducting a Phase 1b/2 trial assessing onvansertib in combination with standard chemotherapy for KRAS-mutated mCRC.